Category: T2 Biosystems Inc.
Shares of T2 Biosystems jump nearly 10% after the FDA approves its MR-based tests designed to detect sepsis in a matter of hours rather than days.
Here's a look at some of the top Wall Street stories for medical device companies this week: FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; Greatbatch acquires Uruguay's CCC Medical Devices; T2 Biosystems IPO raises $57M for MRI-based diagnostics; Strong Q4, $750M buyback give CareFusion a boost; Baxano: Strong Q2, new patents can't appease Wall Street
Diagnostic devices maker T2 Biosystems raises $57 million in an initial public offering after pricing shares below range at $11 apiece.
Massachusetts-based T2 Biosystems (NSDQ:TTOO) fell below target with its initial public offering today, raising $57 million in support of its MRI-based diagnostic systems.
MRI diagnostics maker T2 Biosystems releases details on its initial public offering, hoping to raise as much as $78.2 million at $17 per share.
Massachusetts-based T2 Biosystems raised its hopes for its upcoming initial public offering, raising its maximum aggregate take to $78.2 million if shares sell at $17 apiece.
Here's a look at some of the top Wall Street stories for medical device companies this week: T2 Biosystems prepares $69M IPO for MRI-based diagnostics; Philips Healthcare retools, CEO DiSanzo is out; iRadimed sets terms for $10M IPO
Massachusetts-based T2 Biosystems registers for an initial public offering worth up to $69 million in support of its novel magnetic resonance imaging-based diagnostic systems.
Diagnostics-maker T2 Biosystems is preparing to go public in an offering that could garner as much as $69 million, according to SEC filings.